Skip to main
ZYME

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks is poised for success in the biopharmaceutical industry with its innovative therapeutic platforms and promising pipeline, including zanidatamab, which has recently FDA approved for the treatment of gastroesophageal and other solid tumors that express HER2. In addition to this, Zymeworks' recent acquisition of Theravance brings in substantial royalty opportunities and strengthens its commercial capabilities. With a strong financial position and diverse pipeline, Zymeworks has the potential to be a top-performing stock.

Bears say

Zymeworks is a clinical-stage biopharmaceutical company that faces multiple risks including lower-than-expected revenues and higher-than-expected operating expenses. Despite positive developments in their pipeline, such as the upcoming HER2+ GEA PDUFA and potential approval milestones, the company's current cash balance and upcoming debt repayment may limit their ability to create shareholder value in the near term. Overall, the outlook for Zymeworks is negative due to these risks and limited potential for near-term financial success.

Zymeworks Inc (ZYME) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Buy based on their latest research and market trends.

According to 10 analysts, Zymeworks Inc (ZYME) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.